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Abstract
Background: Externally stenting saphenous vein grafts reduces intimal hyperplasia, improves lumen uniformity and
reduces oscillatory shear stress 1 year following surgery. The present study is the first to present the longer-term (4.
5 years) performance and biomechanical effects of externally stented saphenous vein grafts.
Methods: Thirty patients previously implanted with the VEST external stent in the randomized, within-patient-
controlled VEST I study were followed up for adverse events; 21 of these were available to undergo coronary
angiography and intravascular ultrasound.
Results: Twenty-one stented and 29 nonstented saphenous vein grafts were evaluated by angiography and
ultrasound at 4.5 ± 0.3 years. Vein graft failure rates were comparable between stented and nonstented grafts (30 and
23% respectively; p = 0.42). All failures were apparent at 1 year except for one additional nonstented failure at 4.5 years.
In patent vein grafts, Fitzgibbon perfect patency remained significantly higher in the stented versus nonstented vein
grafts (81 and 48% respectively, p = 0.002), while intimal hyperplasia area (4.27 mm2 ± 1.27 mm2 and 5.23 mm2 ± 1.
83 mm2 respectively, p < 0.001) and thickness (0.36 mm± 0.09 mm and 0.42 mm± 0.11 mm respectively, p < 0.001)
were significantly reduced. Intimal hyperplasia proliferation correlated with lumen uniformity and with the distance
between the stent and the lumen (p = 0.04 and p < 0.001 respectively).
Conclusions: External stenting mitigates saphenous vein graft remodeling and significantly reduces diffuse intimal
hyperplasia and the development of lumen irregularities 4.5 years after coronary artery bypass surgery. Close
conformity of the stent to the vessel wall appears to be an important factor.
Trial registration: NCT01415245. Registered 11 August 2011.
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Background
Saphenous vein grafts (SVG) remain the most com-
monly used conduit in coronary artery bypass grafting
(CABG). However, despite significant advances in under-
standing SVG pathophysiology post implantation, rela-
tively little progress has been made in the clinical setting
- current vein graft failure rates range from 35 to 50% 5
to 10 years following CABG surgery [1]. SVG failure is
attributed to the onset of structural changes in the con-
duit immediately post implantation due to its exposure
to the hemodynamics of the arterial circulation [2]. SVG
remodeling includes an inflammatory response accom-
panied by the development of intimal hyperplasia (IH)
that serves as the foundation for graft thrombosis and
occlusive atherosclerosis [2, 3]. Attempts to mitigate IH
in vein grafts have been the focus of intense clinical re-
search. However, most of the pharmacological thera-
peutic modalities have had a limited effect in the clinical
setting, except for statins and beta-blockers [4–6].
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External stenting of SVGs has long been postulated to
have the potential to lessen adverse mechanical and
structural changes that contribute to SVG deterioration.
In 2015 we reported our first in human experience with
a new cobalt chrome external stent for SVGs (VEST,
Vascular Graft Solutions, Israel) [7]. At 1 year, externally
stented SVGs showed significant reduction in IH, im-
proved lumen uniformity and reduced oscillatory shear
stress compared to non-stented SVGs [7]. Conversely, a
notable limitation was the lower patency rate of exter-
nally stented SVGs to the right compared to the left cor-
onary vessels at 1 year [7]. As recently reported in the
VEST II trial in this journal, avoidance of both metal
clip ligation of SVG side branches and of fixation of the
stent to the anastomoses significantly improved early pa-
tency rates of SVGs to the right coronary territory from
55 to 86% [8]. Currently two larger trials of external
stenting are underway. VEST III (NCT02511834) is a
European multicentre study that completed recruitment
of 180 patients in January 2017. The study endpoints are
major cardiovascular and cerebral events (MACCE) and
graft patency as assessed by CT angiography at 6 months
and 2 years. In the USA a similar 224 patient trial has
recently started recruiting under the auspices of the Car-
diothoracic Surgical Trials Network (VEST Pivotal, NCT
03209609). In the meantime, while several groups have
reported 1-year patency rates there are no data in the lit-
erature regarding patency rates beyond this. The object-
ive of the current VEST IV study was to investigate the




The VEST I study prospectively enrolled 30 CABG pa-
tients with multi-vessel disease who were implanted with
the VEST external stent (Vascular Graft Solutions, Tel
Aviv, Israel) in a within-patient randomized controlled
design, from October 2011 to September 2012 [7]. Eli-
gible patients were scheduled for on-pump multi-vessel
CABG including a left internal mammary artery to the
left anterior descending coronary artery and SVGs to
right and circumflex territories. Eligibility required a tar-
get vessel diameter ≥ 1.5 mm with a coronary stenosis >
75% and with an adequate distal vascular bed, as
assessed by preoperative angiography. Each patient re-
ceived one external stent device to a single SVG, ran-
domly assigned intra-operatively by the opening of a
sealed envelope only after all distal anastomoses were
performed, to either the right or the circumflex coronary
territories. One or more SVG remained non-stented and
served as the control group. All SVGs were harvested in
an open technique. Transit Time Flow Measurement
(TTFM) was determined in all grafts. There was no
significant difference in baseline grafting variables be-
tween stented and control groups (Table 2 of reference
[7]). The primary effectiveness endpoint compared in-
timal hyperplasia area between groups, assessed by intra-
vascular ultrasound (IVUS) at 12 months.
In the current extended follow-up study (VEST IV),
MACCE data were collected for all patients. MACCE
was defined as the composite occurrence of all-cause
mortality, myocardial infarction (MI), revascularization,
and/or stroke. Only patients who were alive and last
known to have at least one patent vein graft were invited
to return for a coronary angiogram and IVUS. Patients
who did not have angiography underwent telephone
follow-up. The study protocol conformed to the Declar-
ation of Helsinki and was approved by a UK Research
Ethics Committee. Each patient gave their informed con-
sent to participate in the study.
Angiography and IVUS
Contrast angiography was attempted for all grafts using
the same camera angles as in VEST I, and using an iden-
tical method of analysis by the same core laboratory.
Quantitative coronary angiography (QAngio XA®, Medis,
The Netherlands) was performed for all patent grafts.
Fitzgibbon grade I, II, or III was assigned to each graft
to determine lumen uniformity: I, no intimal irregularity;
II/III, irregularity of the intimal surface of < 50 and >
50% respectively [9].
IVUS examination was performed along the entire
length of patent vein grafts (40 MHz IVUS catheter with
automated 1.0 mm/s pullback, Boston Scientific, Hemel
Hempstead, UK). Individual cross sectional IVUS im-
ages, approximately 10 mm apart over the entire vein
graft length, were analyzed using QIVUS software
(QIVUS® Medis, The Netherlands). Lumen and external
elastic membrane (EEM) were identified and marked in
accordance with convention [10] by an independent ob-
server. IH area was calculated for every cross-section as
the area between the EEM and the lumen perimeters.
The IH thickness was calculated as the mean EEM ra-
dius minus the mean lumen radius. The VEST was iden-
tified and marked in the stented grafts and its distance
from the lumen was calculated by subtracting the mean
lumen radius from the mean VEST radius. To assess IVUS
intra-observer variability, 11 pullbacks from 6 vein grafts
(3 stented and 3 nonstented) were measured 1 month
apart. IVUS intra-observer variability for EEM cross sec-
tional area was − 0.02 +/− 0.6mm2 (r = 0.99, p = 0.99), and
for lumen was 0.03 +/− 0.24 mm2 (r = 0.99, p = 0.97).
The primary efficacy endpoint compared IH area and
thickness between stented and nonstented groups. Graft
occlusion and Fitzgibbon perfect patency rates were also
compared between the groups. The interaction between
various disease markers obtained from the two imaging
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modalities was quantified by comparing the cross-sec-
tional parameters derived from IVUS across angiograph-
ically perfectly patent (Fitzgibbon I) and patent with
irregularities (Fitzgibbon II/III) graft groups. The effect
of external stent dimensional conformity to the vessel
wall was assessed by computing the correlation between
stent distance from the lumen and IH thickness for the
stented grafts.
Statistical analysis
Descriptive statistics are provided as mean, standard devi-
ation, minimum, median and maximum for continuous
variables and as count and percent for non-continuous var-
iables. Statistical testing was done using a mixed-effect
model repeated measures, using measures taken at 1 and
4.5 year follow-ups. Continuous variables were analyzed
using a linear regression model with ordinal variables ana-
lyzed using logistic regression. In both cases, subject was
included as a random variable in the model. P-values of the
device effect were obtained based on least squares mean es-
timates over both time points, since no interaction with
time was obtained. Missing values at 4.5 years were inputed
by using last observation carried forward from 1 year and
included in the model. Pearson correlations were computed
between wall thickness and plaque-thickness/area at 1 and
4.5 years separately within the stented grafts group; time
points were not combined for this analysis due to the same




Of the 30 patients who underwent randomization and
treatment with the VEST in the original trial, MACCE
data were available for all patients, and angiography and
IVUS measurements were available for 21 patients (70%)
at a mean (±SD) 4.5 ± 0.3 year follow-up. Of the 9 pa-
tients that did not return for angiographic follow-up, 2
had both vein grafts previously known to be occluded
and were not asked to return, 3 were deceased, and 4 re-
fused the procedure. Demographic and medical history
data are provided in Table 1.
Table 1 Clinical characteristics of all patients at randomization and those who underwent follow-up angiography
Characteristic All patients (n = 30) Angiographic follow-up (n = 21)
Age (years) 65 ± 8 65 ± 9
Male 27 (90) 16 (89)
Smoking status:
Current 3 (10) 2 (10)
Ex-smoker 22 (73.3) 15 (71)
Never 5 (16.7) 4 (19)
Diabetes:
IDDM 5 (17) 3 (14)
NIDDM 6 (20) 5 (24)
No history 19 (63) 13 (62)
Hypertension: 20 (66.7) 14 (67)
Hyperlipidemia 29 (96.7) 20 (95)
Prior stroke (non-debilitating) 1 (3.3) 1 (5)
COPD 1 (3.3) 0
NYHA class:
I 11 (36.7) 6 (29)
II 13 (43.3) 9 (43)
III 4 (13.3) 4 (19)
IV 2 (6.7) 2 (9)
LVEF (%) 56 ± 10 55 ± 10
Creatinine (umol/L) 85 ± 18.9 81.7 ± 18.1
Pre-op Logistic EuroSCORE (%) 1.58 ± 1.29 1.7 ± 1.4
Total number grafts/patient 3.3 ± 0.5 3.4 ± 0.5
Days of follow up 1601 ± 102 1601 ± 113
Mean (±SD) or n (%). IDDM insulin dependent diabetes, NIDDM non-insulin dependent diabetes, COPD chronic obstructive pulmonary disease, NYHA New York
Heart Association, LVEF left ventricular ejection fraction
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Clinical outcomes
Three patients (10%) had died since surgery; one was a
cardiac-related death and two were due to cancer. Over-
all 3 patients (10%) experienced one or more MACCE
events. Of 3 revascularization events, one was triggered
by the protocol-mandated angiographic control, one was
to the nonstented territory, and one was to both stented
and nonstented territories. One myocardial infarction
(3.3%) and no strokes were reported.
Vein graft disease markers
Figure 1 shows angiographic images of a within-patient
comparison of stented and nonstented SVGs at 1 and
4.5 year follow-up. Vein graft failure rates at 4.5 years were
comparable between the stented and non-stented graft
groups (Fig. 2). In the stented group, all grafts that were
patent at the 1 year follow up, maintained their patency at
the 4.5 year follow up, however in the non-stented group
there was one additional graft occlusion between 1 and
4.5 years. At 4.5 years, stented vein grafts maintained
perfectly-patent lumens without irregularities at signifi-
cantly higher proportions than non-stented grafts (Fig. 2).
Fig. 3 illustrates IVUS images of a within-patient com-
parison of stented and nonstented SVGs at 1 and 4.5 year
follow-up. IH area and thickness at 4.5 years did not
change significantly compared to 1 year but both were
significantly reduced in the stented versus the non-
stented grafts (Fig. 4). Lumen diameters did not signifi-
cantly differ between the two groups (3.38 ± 0.50 mm vs.
3.45 ± 0.54 mm stented vs. nonstented; p = 0.585).
Grafts with Fitzgibbon I classification had significantly
lower plaque area compared to grafts with Fitzgibbon II/
III (p = 0.04, Table 2). Figure 5 illustrates IVUS images of
a constrictive- and a loose-fitting external stent. The dis-
tance of the stent to SVG wall was positively correlated
with IH thickness both at 1 year (correlation coefficient
0.76, p < 0.001) and at 4.5 years (correlation coefficient
0.84, p < 0.001; Fig. 6).
Discussion
VEST IV is a unique study, presenting for the first time
the long-term follow-up of a randomized controlled trial
evaluating the impact of external stenting of SVGs used
in CABG surgery. Our key finding is that the benefits of
external stents on improving Fitzgibbon perfect patency
and reducing IH that was demonstrated at 1 year are
maintained at 4.5 years. Similarly, with the exception of an
additional vein graft occlusion in the nonstented group,
there was little further deterioration at longer-term follow
up. A second key finding, as discussed subsequently, is
that the distance of the VEST stent from the SVG lumen
was an important determinant of the degree of IH. The
MACCE rate of 18% in this study was comparable to that
reported by the SYNTAX trial group for their 3-vessel dis-
ease subgroup at 4 years and at 5 years post CABG at 19
and 24% respectively [11, 12].
This study strengthens and corroborates previous
pre-clinical and clinical reports suggesting a protective
biomechanical effect of a braided cobalt chrome external
stent on vein graft remodeling [7, 8, 13, 14]. A particular
Fig. 1 Angiographic images showing a within-patient comparison of stented and nonstented SVGs at 1 and 4.5 year follow-up. Stented SVG to
obtuse marginal artery at 1 year (a) and after 4.5 years (b). Nonstented SVG to right coronary artery at 1 year (c) and 4.5 years (d)
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Fig. 2 Perfect patency and graft failure rates of stented and nonstented vein grafts at 1 and 4.5 years post CABG. Green bars - perfect patency
rates within each arm of stented (n = 40) and nonstented (n = 59) grafts (p = 0.002). Grey bars - graft failure rates within each arm of stented (n =
56) and nonstented (n = 72) grafts (p = 0.416)
Fig. 3 Within-patient comparison of intimal hyperplasia using IVUS. Segment of a nonstented SVG to the first obtuse marginal 4.5 years after
implantation without (a) and with (b) marking of the lumen (red), EEM (purple) and outer vessel (green). Segment of externally stented SVG to
the second obtuse marginal 4.5 years after implantation without (c) and with (d) marking of the lumen (red), EEM (purple) and stent (green)
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strength of our trial was the paired study design with
each patient acting as their own control, thereby elimin-
ating many of the potential factors that could affect SVG
disease progression. The stented and nonstented graft
groups were well balanced with respect to baseline ana-
tomical and physiological parameters that might contrib-
ute to the development of IH, including the diameter of
the native coronary artery and the severity of the prox-
imal coronary artery stenosis. This was also evidenced
by the similarity of measured graft flows in both the
stented and nonstented SVGs, intraoperatively by TTFM
and at 1-year by angiography [7]. Furthermore, while
previous IVUS studies on SVGs were limited only to the
proximal part of the grafts at one time point [15], our
study provides, for the first time, new insight into the
diffuse nature of the disease by recording intimal devel-
opment along the entire SVG length at both 1 and
4.5 years.
The early phase of vein graft remodeling is dominated
by luminal enlargement followed by a later phase of vein
graft thickening and IH. Luminal enlargement is gener-
ated mainly by the exposure to the high shear stress of
the arterial circulation [3]. During the first months post
implantation, as a reaction to the elevated wall tension,
there is a proliferative thickening of the venous wall and
changes in wall composition [3]. Hozumi et al. have
shown that between 1 to 12 months post implantation,
intimal area was significantly increased from 0.90 mm2
to 5.26 mm2 (p < 0.001) [15]. Our findings concur with
Hozumi et al., suggesting that most SVG remodeling oc-
curs over the first year after grafting and, consequently,
that early intervention is crucial in order to effectively
lessen the pathological changes which serve as the foun-
dation for occlusive atheromatous lesions 5–10 years fol-
lowing surgery [15]. The mitigation of IH and lumen
deformation achieved by external stenting was most pro-
nounced in the first year after implantation and was
maintained over the subsequent 3.5 years. This observa-
tion is also in line with experimental data on biodegrad-
able external stents which demonstrated that the
majority of the inhibitory effect on SVG remodeling was
achieved 6 months post implantation [16].
In both arteries and veins, lumen irregularities gener-
ate low and oscillatory shear stress that is directly corre-
lated with accelerated vascular disease [13, 17]. A high
proportion of SVGs, mainly from the upper leg, demon-
strate caliber irregularities even during harvesting while
> 25% of SVG show severe segmental ectasia with > 50%
dilatation at 1 year [7]. In their landmark publication,
Fitzgibbon and colleagues described the progression of
SVG disease over the course of 15 years [9]. At 5, 10
and 15 years, only 52, 23 and 19% of the patent grafts
respectively demonstrated “perfect” patency with no
Fig. 4 Comparison of intimal hyperplasia proliferation markers at 1 and 4.5 year follow-up. Data are mean ± SD. IH, intimal hyperplasia; 1Y, 1 year
follow-up; 4.5Y, 4.5 year follow-up. Green square Stented grafts, grey square Non-stented grafts
Table 2 Cross sectional IVUS parameters for Fitzgibbon grade
vein graft groups
Variable Fitzgibbon I Fitzgibbon II & III P value
IH area [mm2] 4.5 (3.9, 5.0) 5.2 (4.5, 5.8) 0.04
IH thickness [mm] 0.4 (0.3, 0.4) 0.4 (0.4, 0.5) 0.09
Lumen diameter [mm] 3.4 (3.2, 3.6) 3.5 (3.3, 3.8) 0.38
Data are mean (95% CI). IH intimal hyperplasia
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lumen irregularities. The diffuse progressive nature of
vein graft disease was further supported by contempor-
ary studies that demonstrate that only 12–25% of SVG
are perfectly patent 10 years after surgery [18]. We
found that reduced SVG lumen irregularity is associated
with decreased intimal area and thickness, most prob-
ably due to the improved hemodynamics and reductions
in oscillatory shear stress provided by external stents
[13, 17]. External stenting prevented SVG deformation
early after implantation and mitigated development of
further lumen irregularities at 4.5 years.
Mechanical external support of SVGs has been a focus
of intense research, with their use intended to reduce
well-documented pathophysiological changes that occur
in the SVG following implantation. These devices have
developed substantially over recent years, and there is
now a large body of data in both animal models and hu-
man patients related to their biomechanical effects [17,
19, 20]. External stenting targets some of the key factors
initiating the pathological cascade in SVG post implant-
ation such as high circumferential wall stress and disturbed
flow patterns due to luminal irregularities [13, 14, 17]. The
rationale and the physiological basis for mechanical exter-
nal stents is further supported by the reported benefits of
the “no touch” technique, in which the saphenous vein is
harvested with a pedicle of surrounding tissue that serves
as an external support with both mechanical and biological
roles [21]. Randomized prospective studies showed that no
Fig. 5 IVUS images showing a constrictive versus b loose fitting external stent (red arrows). Difference in wall thickness (yellow) and intima layer
(blue) can be observed. In addition, there is formation of “neo-adventitia” between the loose-fitting stent and the original vessel wall
Fig. 6 Intimal hyperplasia thickness correlated with distance of the external stent from the lumen. grey circle 1 year (correlation coefficient 0.76, p< 0.001),
green circle 4.5 years (correlation coefficient 0.84, p< 0.001). Baseline saphenous vein wall thickness (−--) is derived from relevant literature [30, 31]
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touch technique is associated with superior patency rates
compared with conventionally prepared vein grafts both in
the short-term (18 months) and long-term (8.5 years) at
angiographic follow-up [22, 23].
Early clinical experience with external stents showed
conflicting data with early patency rates ranging from 28
to 92% at 6–12 months [24, 25]. High SVG failure rates
were attributed to the design of the first generation of
external stents that required incorporation of the device
into the anastomoses, constriction of the graft and fix-
ation of the stent to the SVG with fibrin glue [25]. Sev-
eral studies have shown that fibrin glue on the external
surface of vein grafts lead to aneurysmal degeneration
and excessive IH which may jeopardize vein graft pa-
tency [25–27]. Second generation technologies which
did not require the use of fibrin glue or incorporation to
the anastomoses site showed comparable patency rates
to non-stented SVG at 1 year [7].
The appropriate size of external stents for vein grafts
has been a focus of controversy and another possible
confounding factor for success of external stenting. Zilla
and colleagues concluded that constrictive external
stents, which reduce diameter mismatch with the target
artery, are more effective in mitigating IH compared to
non-restrictive stents [28]. In contrast, Izzat and col-
leagues have shown that loose-fitting external stents are
more effective in suppressing intimal proliferation [29].
The rationale behind using oversized external supports
was to provide sufficient space to promote adventitial
neovascularization, which was potentially interrupted by
constrictive stents [20]. The distance of the external
stent from the lumen is equivalent to the SVG wall
thickness. The closer this measure is to the vein baseline
wall thickness, the better the conformity of the VEST to
the vein. We postulated that a closer conformity would
improve VEST performance in mitigating IH, and indeed
we found that the correlation between the distance of
the VEST from the lumen and the IH thickness was in-
deed significant in our study. As shown in Fig. 6, the
closer the value is to the baseline literature reported vein
wall thickness, the lesser the proliferation of IH [30, 31].
This finding suggests that mildly constricting the vein
has a beneficial effect on intimal proliferation, most
probably due to more effective reduction in wall tension,
SVG dilatation, and lumen irregularities. It is expected
that future studies, in which appropriate model selection
will ensure a mildly constrictive stent, a more effective
reduction in IH will be achieved.
Limitations
Together with the small sample size, a further limitation
of our study is that the study cohort was based on a first
in human trial and exhibited learning curve effects of both
the technology and the implantation technique (which
were largely resolved in VEST II [8]). The technical fail-
ures and inappropriate model selection, with suboptimal
dimensional match between the SVG and the stent, likely
have adversely affected the stent’s ability to even more ef-
fectively mitigate IH. VEST III, a large randomized trial
that is currently underway (NCT02511834), will address
both the population size and learning curve issues.
Conclusion
Improving SVG longevity may have a direct impact on
the clinical outcome of CABG and patients’ quality of
life. Our study provides novel insights into the biomech-
anical effects of external stenting of SVGs and their
long-term performance – to our knowledge, the only
long-term follow-up of external stenting to SVGs to
date. If the beneficial effect of external stenting that we
observed at one and 4.5 years is maintained over a 10–
15 year period, it may have a substantial impact on im-
proving clinical outcomes. Future and ongoing large ran-
domized trials with long-term follow up will further
determine the role of external stents in CABG surgery.
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